{"entity":{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","aka":[],"tldr":"Breast trialist who co-led OlympiA, showing adjuvant olaparib improves survival in BRCA carriers.","summary":"Charles Geyer Jr. is a breast cancer trial leader with NRG Oncology and Professor of Medicine at the University of Pittsburgh. A medical oncologist and long-time NSABP/NRG leader, he co-chaired OlympiA, the trial of adjuvant olaparib in germline BRCA carriers, led NSABP B-31 analyses of adjuvant trastuzumab, and led the KATHERINE trial of trastuzumab emtansine for residual disease. His papers report the overall survival analysis of the OlympiA phase III trial in Annals of Oncology and trastuzumab emtansine for residual invasive HER2-positive breast cancer in the New England Journal of Medicine. His work covers triple-negative, HR-positive and HER2-positive breast cancer, PARP inhibitors and HER2.","asOf":"2026-09-08","links":[{"label":"NRG Oncology","url":"https://www.nrgoncology.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Geyer%20CE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Charles%20E.%20Geyer%20Jr."}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":["brca","parp","her2"],"drugs":["olaparib","trastuzumab-emtansine"],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":["olympia","katherine","hera-b31-n9831"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"role":"Breast cancer trial leader, NRG Oncology; Professor of Medicine, University of Pittsburgh","institutionId":"nrg-oncology","specialisms":["Breast cancer","Adjuvant therapy","PARP inhibitors"],"profiles":[{"label":"NRG Oncology","url":"https://www.nrgoncology.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Geyer%20CE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Charles%20E.%20Geyer%20Jr."}],"papers":[{"title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","journal":"Annals of Oncology","year":2022,"url":"https://doi.org/10.1016/j.annonc.2022.09.159","doi":"10.1016/j.annonc.2022.09.159"},{"title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","journal":"New England Journal of Medicine","year":2019,"url":"https://doi.org/10.1056/NEJMoa1814017","doi":"10.1056/NEJMoa1814017"},{"title":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2105215","doi":"10.1056/NEJMoa2105215"}]},"route":"/people/charles-geyer/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"}],"company":[{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/"}],"trial":[{"id":"brightness","kind":"trial","name":"BrighTNess","route":"/trials/brightness/"},{"id":"hera-b31-n9831","kind":"trial","name":"HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)","route":"/trials/hera-b31-n9831/"},{"id":"katherine","kind":"trial","name":"KATHERINE","route":"/trials/katherine/"},{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/"}],"journal":[{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/"}],"paper":[{"id":"paper-katherine-nejm-2019","kind":"paper","name":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","route":"/key-papers/paper-katherine-nejm-2019/"},{"id":"paper-geyer-brightness-4-year-follow-up-ann-oncol-2022","kind":"paper","name":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","route":"/key-papers/paper-geyer-brightness-4-year-follow-up-ann-oncol-2022/"},{"id":"paper-olympia-nejm-2021","kind":"paper","name":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","route":"/key-papers/paper-olympia-nejm-2021/"},{"id":"paper-olympia-overall-survival-ann-oncol-2022","kind":"paper","name":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","route":"/key-papers/paper-olympia-overall-survival-ann-oncol-2022/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}]}}